| Date | Title | Description |
| 02.05.2024 | Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 | PDUFA Target Action Date of June 26, 2024
Eight posters including two oral presentations support potential of ensifentrine,
an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4
LONDON and RALEIGH, N.C., May 02, 202... |
| 29.02.2024 | Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | PDUFA Target Action Date for ensifentrine of June 26, 2024
Commercialization preparations advance
Strong balance sheet supports commercialization and Company's growth
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH... |
| 20.07.2023 | Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update | /EIN News/ -- LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it wil... |
| 28.06.2023 | Nuance Pharma's Partner Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD | SHANGHAI, June 28, 2023 /PRNewswire/ -- Nuance Pharma announces its partner, Verona Pharma plc (Nasdaq: VRNA), has submitted a New Drug Application ("NDA") to the US Food and Drug Administration ("FDA") for approval of e... |
| 27.06.2023 | Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD | /EIN News/ -- LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration ... |
| 24.05.2023 | Verona Pharma to Present at Jefferies Healthcare Conference | /EIN News/ -- LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the Jefferies Healthcare Confe... |
| 02.05.2023 | Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023 | 12 Abstracts and one Symposium further support potential of ensifentrine,
a first-in-class, selective, dual inhibitor of PDE3 and PDE4
Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST
LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEW... |
| 07.04.2023 | Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD") | SHANGHAI, April 7, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"... |
| 07.04.2023 | Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD") | SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD"... |
| 20.12.2022 | Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD | Statistically significant improvements in lung function, symptoms and quality of life
36% reduction in rate of exacerbations over 24 weeks
Well tolerated safety profile over 48 weeks
NDA submission planned for 1H 2023
Conference call today ... |
| 09.11.2022 | Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update | /EIN News/ -- Access to up to $400 million expected to provide cash runway through at least 2025
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C.... |
| 26.10.2022 | Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its f... |
| 17.10.2022 | Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance | LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt facility”) providing the Company with access to ... |
| 29.08.2022 | Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference | LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Inve... |
| 24.08.2022 | Verona Pharma strengthens commercialization leadership team | LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for comme... |
| 19.08.2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, ... |
| 19.08.2022 | Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China | LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc VRNA ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development... |
| 19.08.2022 | Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China | SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinic... |
| 19.08.2022 | Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China | SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinic... |
| 15.08.2022 | Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs | LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its ... |
| 10.08.2022 | Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering | LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its ... |
| 09.08.2022 | Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update | Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON a... |
| 09.08.2022 | Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD | Statistically significant improvements in key measures of lung function
42% reduction in rate of exacerbations over 24 weeks
Well tolerated with safety results similar to placebo
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON... |
| 09.08.2022 | Verona Pharma plc Announces Proposed Underwritten Public Offering | LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwri... |
| 08.08.2022 | Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD | LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will re... |
| 29.07.2022 | Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 09.06.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed pa... |
| 06.06.2022 | Verona Pharma to Host KOL Event on June 16, 2022 | LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), today announces it will host an in-person KOL event for analysts and investors on Thursday, June 16, 2022, at 8:00 AM ET, in New... |
| 25.05.2022 | Verona Pharma to Present at Jefferies Healthcare Conference | LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a company overview at the Jefferies Healthcare Con... |
| 09.05.2022 | Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022 | LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of an abstract demonstrati... |
| 04.05.2022 | Verona Pharma Announces May 2022 Investor Conference Participation | LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:
LifeSci Partners Virtual Immunology & Inflam... |
| 03.05.2022 | Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update | Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022
James Brady joined the Board as Non-Executive Director
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., May 03, 2022 (GLOBE NEWSWIRE) ... |
| 19.04.2022 | Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results... |
| 14.03.2022 | James Brady Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a... |
| 03.03.2022 | Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update | Phase 3 ENHANCE program on track to report top-line COPD data in 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or t... |
| 17.02.2022 | Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | Top-line Data Expected in the Third Quarter of 2022
LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respi... |
| 24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed pa... |
| 05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset | ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022
LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| 05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset | ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022
ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022
LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Veron... |
| 04.01.2022 | Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference | LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 04.01.2022 | Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference | LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 16.12.2021 | Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction | LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces ensifentrine met all safety objectiv... |
| 16.12.2021 | Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction | Study Supports Ongoing Phase 3 Program and Planned NDA Submission
LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respirat... |
| 09.11.2021 | Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021
ENHANCE Phase 3 program on track to report top-line data in 2022
Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT
LONDON and RALEIGH, N.C.,... |
| 01.11.2021 | Verona Pharma Announces November 2021 Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 01.11.2021 | Verona Pharma Announces November 2021 Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 26.10.2021 | Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 13.10.2021 | Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021 | LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of Phase 2 data demonstra... |
| 13.10.2021 | Verona Pharma : to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021 | Bronchodilation demonstrated with pMDI, consistent with DPI and nebulizer formulations
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical compan... |
| 05.08.2021 | Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update | ENHANCE Phase 3 program on track to report top-line data in 2022
Up to $219 million strategic collaboration with Nuance Pharma in Greater China
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON and RALEIGH, N.C., Aug. 05, 2021 (... |
| 27.07.2021 | Verona Pharma Announces August 2021 Virtual Investor Conference Participation | LONDON and RALEIGH, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., Preside... |
| 22.07.2021 | Verona Pharma to Report Second Quarter 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 10.06.2021 | Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China | LONDON and RALEIGH, N.C., and SHANGHAI, June 10, 2021 /PRNewswire/ -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma") and Nuance Pharma Limited ("Nuance Pharma"), today announce that the companies have entered into an... |
| 25.05.2021 | VERONA PHARMA PLC
Verona Pharma to Present at Jefferies Virtual Healthcare Conference | LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Off... |
| 04.05.2021 | VERONA PHARMA PLC
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference | LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces three abstracts highlighting new analyses f... |
| 29.04.2021 | VERONA PHARMA PLC
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update | ENHANCE Phase 3 program enrollment continues on track to complete in 2H21
Board strengthened with NED appointment of Lisa Deschamps
Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSW... |
| 27.04.2021 | VERONA PHARMA PLC
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease | LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of efficacy and safety result... |
| 23.04.2021 | VERONA PHARMA PLC
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 | LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces data from a pilot study of a pressurized ... |
| 21.04.2021 | VERONA PHARMA PLC
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results... |
| 02.03.2021 | Lisa Deschamps Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Descha... |
| 01.03.2021 | Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference | LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive O... |
| 18.02.2021 | Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 18.02.2021 | VERONA PHARMA PLC
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update | LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results ... |
| 02.02.2021 | VERONA PHARMA PLC
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD | Primary and secondary lung function endpoints met
Results support twice-daily dosing
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company ... |
| 02.02.2021 | VERONA PHARMA PLC
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD | LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit "µg" were mistakenly represented... |
| 14.01.2021 | VERONA PHARMA PLC
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 | LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment (n=45) in its ... |
| 05.01.2021 | VERONA PHARMA PLC
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference | LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Of... |
| 24.11.2020 | Verona Pharma : Secures up to $30 Million Debt Financing from Silicon Valley Bank | LONDON - Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered into a debt financing facility for up to $30 million ('d... |
| 24.11.2020 | VERONA PHARMA PLC
Verona Pharma : Secures up to $30 Million Debt Financing from Silicon Valley Bank | LONDON - Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered into a debt financing facility for up to $30 million ('d... |
| 23.11.2020 | Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank | - |
| 23.11.2020 | VERONA PHARMA PLC
Verona Pharma : Secures up to $30 Million Debt Financing from Silicon Valley Bank | Non-dilutive capital to provide further financial flexibility
LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focuse... |
| 23.11.2020 | Verona Pharma : Secures up to $30 Million Debt Financing from Silicon Valley Bank | Non-dilutive capital to provide further financial flexibility
LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focuse... |
| 09.11.2020 | VERONA PHARMA PLC
Verona Pharma : Announces November 2020 Virtual Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that
David Zaccardelli, Chief Executive Of... |
| 09.11.2020 | VERONA PHARMA PLC
Verona Pharma Announces November 2020 Virtual Investor Conference Participation | LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Of... |
| 28.10.2020 | VERONA PHARMA PLC
Verona Pharma plc : Update on AIM Delisting | LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended Delisting and Cancellation of its Ordinary Sh... |
| 22.10.2020 | VERONA PHARMA PLC
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update | LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its unaudit... |
| 21.09.2020 | VERONA PHARMA PLC
Verona Pharma : Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.
NOT FOR REL... |
| 17.09.2020 | Verona Pharma Raises $200Million in Oversubscribed Private Placement and Subscription | - |
| 17.07.2020 | VERONA PHARMA PLC
Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.
NOT FOR REL... |
| 17.07.2020 | Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription | - |
| 13.01.2020 | PACT Pharma bags $75M for neoantigen TCR work, manufacturing; Bayer grabs experimental contraceptive from Daré | → With a new president and chief technical officer in place, next-gen T cell therapy player PACT Pharma has $75 million in fresh financing to expand the scope of its nascent clinical programs and open its own manufactur... |
| 27.04.2017 | Term Sheet — Thursday, April 27 | PETER PAN NEVER HAD TO GROW UP
The following article is from Fortune’s latest issue.
Paid Content What you need to know about growing cyberattacks From ExtraHop
They’re so exuberant, one VC even declared on CNBC that this year “could be one... |
| 04.04.2017 | Allergan vet takes the CEO’s job at Third Rock’s Relay; Verona Pharma files $86M IPO | Sanjiv Patel
→ Third Rock Ventures has recruited Allergan’s chief strategy officer, Sanjiv Patel, to take the helm at its startup Relay Therapeutics. As is common with Third Rock creations, one of the partners took the ... |
| 04.04.2017 | Verona files for $86M IPO to fund COPD, cystic fibrosis trials | Verona Pharma has filed to raise up to $86 million (€81 million) through a Nasdaq IPO. The British respiratory disease specialist is seeking the money to bankroll midphase clinical trials of RPL554 in patients with chronic obstructive pulmo... |
| 20.06.2016 | Verona raises £45M from A-list backers for PhIIb COPD trial, plans Nasdaq listing | Verona Pharma (LON:VRP) has secured £44.7 million ($65.6 million) from big-name investors on both sides of the Atlantic. The cash will enable Verona to deliver Phase IIb data on its PDE3/PDE4 inhibitor RPL554 in patients with chronic obstru... |
